<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875886</url>
  </required_header>
  <id_info>
    <org_study_id>NL54748.078.15</org_study_id>
    <nct_id>NCT02875886</nct_id>
  </id_info>
  <brief_title>DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease</brief_title>
  <acronym>DD</acronym>
  <official_title>DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <brief_summary>
    <textblock>
      In this clinical study the anti-hypertensive response to dietary salt restriction is compared&#xD;
      with the anti-hypertensive response to the diuretics hydrochlorothiazide/amiloride in adult&#xD;
      patients with chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic kidney disease (CKD) are exquisitely salt-sensitive. Salt-sensitivity&#xD;
      in CKD is linked to hypertension and cardiovascular outcomes. Dietary salt restriction is an&#xD;
      accepted intervention for salt-sensitivity in CKD. Another strategy, however, could be to&#xD;
      block sodium uptake by the kidney pharmacologically by diuretics. Especially diuretics acting&#xD;
      on the distal tubule may be effective, because this appears to be the site of increased&#xD;
      sodium reabsorption in CKD. It is currently unknown how these two strategies, diet or&#xD;
      diuretics, relate. The investigators hypothesize that diuretics are non-inferior to diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour blood pressure</measure>
    <time_frame>Two weeks after start of each intervention</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Diuretic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive amiloride and hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-sodium diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are put on a low-sodium diet (60 mmol/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Combined with hydrochlorothiazide</description>
    <arm_group_label>Diuretic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Combined with amiloride</description>
    <arm_group_label>Diuretic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-sodium diet</intervention_name>
    <arm_group_label>Low-sodium diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  CKD stage 3 or 4 (MDRD-GFR 15-60 ml/min)&#xD;
&#xD;
          -  Use of any anti-hypertensive drugs&#xD;
&#xD;
          -  No anti-hypertensive drugs but an average office systolic blood pressure &gt; 140 mmHg&#xD;
             (as measured by datascope)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Salt-wasting CKD&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Severe heart failure (NYHA III or IV) or liver cirrhosis with ascites and the&#xD;
             inability to withdraw diuretics&#xD;
&#xD;
          -  Rapidly declining kidney function with high likelihood of dialysis or kidney&#xD;
             transplantation in the coming 4 months&#xD;
&#xD;
          -  Kidney transplant recipients&#xD;
&#xD;
          -  Use of immunosuppressive drugs&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Previous intolerance or allergy to hydrochlorothiazide or amiloride&#xD;
&#xD;
          -  Serum sodium &lt; 135 mmol/l&#xD;
&#xD;
          -  Serum potassium &lt; 3.5 mmol/l or &gt; 5.0 mmol/l&#xD;
&#xD;
          -  Inability to adhere to the study protocol (due to language, incapacitated subjects,&#xD;
             subjects with intellectual disability)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewout J Hoorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Meng L, Fu B, Zhang T, Han Z, Yang M. Salt sensitivity of blood pressure in non-dialysis patients with chronic kidney disease. Ren Fail. 2014 Apr;36(3):345-50. doi: 10.3109/0886022X.2013.866008. Epub 2013 Dec 17.</citation>
    <PMID>24345270</PMID>
  </reference>
  <reference>
    <citation>McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2015 Feb 18;(2):CD010070. doi: 10.1002/14651858.CD010070.pub2. Review. Update in: Cochrane Database Syst Rev. 2021 Jun 24;6:CD010070.</citation>
    <PMID>25691262</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171-82. doi: 10.1159/000358603. Epub 2014 Feb 11.</citation>
    <PMID>24526255</PMID>
  </reference>
  <reference>
    <citation>Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD, Goldschmeding R, Navis G. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin J Am Soc Nephrol. 2011 Aug;6(8):1845-50. doi: 10.2215/CJN.08190910. Epub 2011 Jul 22.</citation>
    <PMID>21784839</PMID>
  </reference>
  <reference>
    <citation>Levy Yeyati N, Fellet A, Arranz C, Balaszczuk AM, Adrogu√© HJ. Amiloride-sensitive and amiloride-insensitive kaliuresis in advanced chronic kidney disease. J Nephrol. 2008 Jan-Feb;21(1):93-8.</citation>
    <PMID>18264941</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ewout Hoorn</investigator_full_name>
    <investigator_title>Internist nephrologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

